Asian Growth Companies Insiders Are Betting On

Yahoo

6 hours ago

As geopolitical tensions and trade-related concerns continue to shape global markets, Asian stocks have experienced mixed outcomes, with China's benchmark indices slightly declining amidst deflationary pressures and Japan's market showing varied returns. In this environment, companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business.
Name
Insider Ownership
Earnings Growth
Vuno (KOSDAQ:A338220)
15.6%
109.8%
Techwing (KOSDAQ:A089030)
18.8%
68%
Suzhou Sunmun Technology (SZSE:300522)
35.4%
77.7%
Sineng ElectricLtd (SZSE:300827)
36%
26.9%
Shanghai Huace Navigation Technology (SZSE:300627)
24.3%
23.5%
Samyang Foods (KOSE:A003230)
11.7%
24.3%
Nanya New Material TechnologyLtd (SHSE:688519)
11%
63.3%
M31 Technology (TPEX:6643)
30.8%
63.4%
Laopu Gold (SEHK:6181)
35.5%
40.3%
Fulin Precision (SZSE:300432)
13.6%
43%
Click here to see the full list of 611 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.
Let's explore several standout options from the results in the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: China Ruyi Holdings Limited is an investment holding company involved in content production and online streaming across Mainland China, Hong Kong, Europe, and internationally, with a market cap of HK$33.99 billion.
Operations: The company's revenue is primarily derived from its online streaming and online gaming businesses, which account for CN¥3.51 billion, followed by its content production business generating CN¥127.04 million.
Insider Ownership: 16.9%
Revenue Growth Forecast: 27.4% p.a.
China Ruyi Holdings is poised for significant growth, with revenue expected to increase by 27.4% annually, outpacing the Hong Kong market. Earnings are projected to grow at 87.88% per year, with profitability anticipated within three years. However, return on equity is forecasted to remain low at 10.7%. Despite recent shareholder dilution and a net loss due to non-operating items in fiscal 2024, insider ownership remains substantial without notable trading activity in the past three months.
Delve into the full analysis future growth report here for a deeper understanding of China Ruyi Holdings.
Our expertly prepared valuation report China Ruyi Holdings implies its share price may be too high.
Simply Wall St Growth Rating: ★★★★★★
Overview: Akeso, Inc. is a biopharmaceutical company focused on the research, development, manufacture, and commercialization of antibody drugs globally, with a market cap of HK$88.73 billion.
Operations: The company generates revenue of CN¥2.12 billion from its activities in the research, development, production, and sale of biopharmaceutical products.
Insider Ownership: 18.9%
Revenue Growth Forecast: 29.7% p.a.
Akeso is positioned for robust growth with revenue forecasted to rise by 29.7% annually, surpassing the Hong Kong market's average. The company is expected to achieve profitability within three years, with earnings projected to grow at 58.28% per year and a high return on equity of 21.7%. Recent approvals of innovative therapies like cadonilimab and ivonescimab enhance its oncology portfolio, although recent financials show a net loss due to decreased revenue from CNY 4.53 billion to CNY 2.12 billion.
Dive into the specifics of Akeso here with our thorough growth forecast report.
Our valuation report here indicates Akeso may be overvalued.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Caliway Biopharmaceuticals Co., Ltd. develops drugs for aesthetic medicine and chronic inflammation, with a market cap of NT$155.38 billion.
Operations: Caliway Biopharmaceuticals Co., Ltd., along with its subsidiaries, focuses on developing pharmaceuticals targeting aesthetic medicine and chronic inflammation.
Insider Ownership: 24.3%
Revenue Growth Forecast: 81.1% p.a.
Caliway Biopharmaceuticals is poised for significant growth, with revenue expected to increase by over 81% annually, outpacing the Taiwan market. The company is on track to achieve profitability in three years. Recent regulatory milestones include FDA support for its innovative drug CBL-514, targeting measurable fat reduction. Despite a first-quarter net loss of NT$175.57 million, these developments provide a solid foundation for future growth and strategic advancement in biopharmaceuticals.
Take a closer look at Caliway Biopharmaceuticals' potential here in our earnings growth report.
The analysis detailed in our Caliway Biopharmaceuticals valuation report hints at an inflated share price compared to its estimated value.
Access the full spectrum of 611 Fast Growing Asian Companies With High Insider Ownership by clicking on this link.
Curious About Other Options? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include SEHK:136 SEHK:9926 and TWSE:6919.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email [e-mail]